0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > CD163

CD163

Brief Information

Name:Scavenger receptor cysteine-rich type 1 protein M130
Target Synonym:CD163,M130,Scavenger receptor cysteine-rich type 1 protein M130,sCD163,CD163 Molecule,Hemoglobin Scavenger Receptor,CD163 Antigen,Macrophage-Associated Antigen,SCARI1,MM130
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

Por estado del producto :
Por categoría de producto :
Por especies :
Por etiqueta :
Por Conjugado::
Cat. No. Especies Descripción del producto Estructura Pureza Característica
CD3-H52E8 Human Human CD163 Protein, His Tag
CD3-H52E8-structure
CD3-H52E8-sds
ACRO Quality

Synonym Name

CD163,M130

Background

Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tetrachlorodecaoxide TCDO; WF-10; OXO-K993 Approved Nuvox Pharma LLC WF10, Oxoferin, Immunokine Thailand Rhinitis, Allergic; Inflammation null 1997-01-01 Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation Details
Tetrachlorodecaoxide TCDO; WF-10; OXO-K993 Approved Nuvox Pharma LLC WF10, Oxoferin, Immunokine Thailand Rhinitis, Allergic; Inflammation null 1997-01-01 Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OR-2805 OR-2805 Phase 2 Clinical OncoResponse Inc Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
OR-2805 OR-2805 Phase 2 Clinical OncoResponse Inc Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje